STOCK TITAN

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Co-Diagnostics, Inc. will be presenting at the H.C. Wainwright & Co. 25th Annual Global Investment Conference to discuss the progress on its forthcoming Co-Dx PCR Home platform. The presentation will be held on September 12, 2023, at 2:30 PM Eastern Time. The platform is subject to FDA review and is not available for sale.
Positive
  • None.
Negative
  • None.

SALT LAKE CITY, Sept. 7, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 25th Annual Global Investment Conference, being held virtually and in-person on September 11-13 in New York City, New York.

Dwight Egan, Company CEO, will be conducting a presentation discussing Company progress on its forthcoming Co-Dx PCR Home™ platform. The presentation can be accessed by clicking here or through the Events and Webcasts section of the Co-Diagnostics website on September 12, 2023 at 2:30 PM Eastern Time, for institutional investors and industry professionals who have registered for the event. 

The Company will also be participating in one-on-one meetings, which can be arranged with H.C. Wainwright representatives.

The Co-Dx PCR Home platform is subject to FDA review and is not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-the-hc-wainwright-25th-annual-global-investment-conference-on-september-11-13-2023-301920689.html

SOURCE Co-Diagnostics

FAQ

What is the upcoming event that Co-Diagnostics, Inc. will be presenting at?

Co-Diagnostics, Inc. will be presenting at the H.C. Wainwright & Co. 25th Annual Global Investment Conference.

What will be discussed during the presentation?

The presentation will discuss the progress on Co-Diagnostics' forthcoming Co-Dx PCR Home platform.

When and where will the presentation be held?

The presentation will be held on September 12, 2023, at 2:30 PM Eastern Time.

Is the Co-Dx PCR Home platform available for sale?

No, the platform is subject to FDA review and is not available for sale.

Co-Diagnostics, Inc.

NASDAQ:CODX

CODX Rankings

CODX Latest News

CODX Stock Data

38.96M
31.91M
5.4%
14.67%
0.71%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SALT LAKE CITY